

Contents

Introduction. O. Slanař, F. Perlík

ix

Reviews

In vitro and in vivo experimental hepatotoxic models in liver research: Applications to the assessment of potential hepatoprotective drugs. H. Farghali, M. Kgalalelo Kemelo, L. Wojnarová, N. Kutinová Canová (*Inst. Pharmacol., Fac. Med., Charles Univ., Prague, Czech Republic*) **S417**

Bile acids, nuclear receptors and cytochrome P450. J. Juřica, G. Dovrtělová, K. Nosková, O. Zendulka (*Dept. Pharmacol., Fac. Med., Masaryk Univ., Brno, Czech Republic*) **S427**

Athymic nude mice as an experimental model for cancer treatment. I. Szadvari, O. Krizanova, P. Babula (*Dept. Physiol., Fac. Med., Masaryk Univ., Brno, Czech Republic*) **S441**

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors. R. Demlova, D. Valík, R. Obermannova, L. Zdražilová-Dubská (*Dept. Pharmacol., Fac. Med., Masaryk Univ., Brno, Czech Republic*) **S455**

Original Articles

Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome. K. Hronová, P. Pokorná, L. Posch, O. Slanař (*Inst. Pharmacol., Fac. Med., Charles Univ., Prague, Czech Republic*) **S463**

Sedative effects of intranasal oxytocin in rabbits and rhesus monkeys. L. Hess, M. Votava, J. Málek, A. Kurzová, J. Slíva (*Dept. Lab. Exp. Anaesth., Inst. Clin. Exp. Med., Prague, Czech Republic, Dept. Pharmacol., Fac. Med., Charles Univ., Prague, Czech Republic*) **S473**

Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma. J. Merhautová, P. Vychytilová-Faltejsková, R. Demlová, O. Slabý (*Mol. Oncol. II., CEITEC, Masaryk Univ., Brno, Czech Republic*) **S481**

Pharmacokinetics of boldine in control and Mrp2-deficient rats. J. Cermanova, A. Prasnicka, E. Dolezelova, L. Rozkydalova, M. Hroch, J. Chládek, P. Tomsik, I. Kloeting, S. Micuda (*Dept. Pharmacol., Fac. Med., Charles Univ., Hradec Kralove, Czech Republic*) **S489**

The effect of (-)-linalool on the metabolic activity of liver CYP enzymes in rats. K. Nosková, G. Dovrtělová, O. Zendulka, R. Řemínek, J. Juřica (*Dept. Pharmacol., Fac. Med., Masaryk Univ., Brno, Czech Republic*) **S499**

Nilotinib induces ER stress and cell death in H9c2 cells. D. Lekes, I. Szadvari, O. Krizanova, K. Lopusna, I. Rezuchova, M. Novakova, Z. Novakova, T. Parak, P. Babula (*Dept. Physiol., Fac. Med., Masaryk Univ., Brno, Czech Republic*) **S505**

Hypertriglyceridemic rats fed high fat diet as a model of metabolic syndrome. B. Kaprinay, B. Lipták, L. Slovák, K. Švík, V. Knezl, R. Sotníková, Z. Gáspárová (*Inst. Exp. Pharmacol., Slovak Acad. Sci., Bratislava, Slovak Republic*) **S515**

Cover Picture

Originally published in the paper: *In vitro* and *in vivo* experimental hepatotoxic models in liver research: Applications to the assessment of potential hepatoprotective drugs. H. Farghali, M. Kgalalelo Kemelo, L. Wojnarová, N. Kutinová Canová (*Inst. Pharmacol., Fac. Med., Charles Univ., Prague, Czech Republic*) – *Physiol Res 65 (Suppl. 4): S422, 2016*